Research Funding from Janssen Research & Development, LLC: "Immunomodulatory effects of single-agent ibrutinib treatment in chronic lymphocytic leukemia patients", Ruolo: Principal Investigator (2016 – presente).
Research Funding from Karyopharm Therapeutics Inc., a Delaware corporation: "In vitro evaluation of the activity of Selinexor (KPT-330) in combination with antineoplastic agents against chronic lymphocytic leukemia primary cells", Ruolo: Principal Investigator (2014 – presente).
Sponsored Phase I/III clinical trials investigating the efficacy of innovative treatments in chronic lymphocytic leukemia. Role: Principal Investigator (2014 - presente).
AIRC19653 Fellowship: “Exploring the regulation of HIF-1α and its potential for therapeutic intervention in chronic lymphocytic leukemia”.
AIRC16343 Fellowship: “Understanding the CXCL12/CXCR4 axis and mevalonate pathway cross-talk to overcome fludarabine resistance in CLL”.
Active participation to the research and clinical projects of ERIC, GIMEMA gruppo linfoproliferative croniche.